Yang Xiaolei from the Drug Registration Division of Beijing Municipal Drug Administration led a team to visit GeneCradle for research and held discussions on the characteristics of the gene therapy industry and the development of representative companies. Relevant personnel from the Drug Registration Division, Drug Review and Inspection Center, the Third Branch of the Municipal Drug Administration and the Beijing Economic and Technological Development Zone Management Committee's Biomedicine Working Group jointly participated in this visit and research activity.
Recently, Yang Xiaolei from the Drug Registration Management Office of the Beijing Municipal Drug Administration (hereinafter referred to as the "Municipal Drug Administration") led a team to visit Beijing Economic and Technological Development Zone to investigate the drug research and development and corporate development of Beijing GeneCradle Technology Co., Ltd. The purpose of the Beijing Municipal Drug Administration's visit and investigation is to better understand the operating conditions and difficulties of drug research and development companies and production companies, and to help establish an effective form of communication with the National Bureau. GeneCradle has received special attention as a representative company in the gene therapy innovative drug research and development industry. The Municipal Drug Administration Research Group has an in-depth understanding of GeneCradle's drug research and development, clinical progress, and pharmaceutical production, and has provided valuable practical guidance. At the symposium, the research team also proposed that it hopes to help the Municipal Bureau better understand the industry characteristics of gene therapy and jointly promote the development of innovative industries by understanding the problems encountered by representative companies in the product development process and commercial production stage.
About GeneCradle
Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with AAV vector delivery technology-mediated gene therapy drug development as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.